Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (81-90 of 153) with videos related to

Pageof 16
Sort By:
The Medical Journal of Australia|May 25, 2020
Candida auris in an Australian health care facility: importance of screening high risk patientsLeon J Worth, Simon J Harrison, Michael Dickinson, et al.
Advances in Therapy|February 2, 2026
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect ComparisonNieves Lopez-Muñoz, Noffar Bar, Joris Diels, et al.
British Journal of Haematology|October 27, 2024
Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T-cell period: Preservation of vaccine-associated antibodies between 0 and 6 monthsGemma K Reynolds, Emily Klimevski, Natalie R Saunders, et al.
Blood|August 31, 2019
Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndromeCrystal Gao, Christopher McCormack, Carrie van der Weyden, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
Blood|February 5, 2011
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopeniaMark J Bishton, Simon J Harrison, Benjamin P Martin, et al.
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
Leukemia & Lymphoma|July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantSimon J Harrison, Andy K Hsu, Paul Neeson, et al.
Pageof 16

Showing results (81-90 of 153) with videos related to

Sort By:
Pageof 16
The Medical Journal of Australia|May 25, 2020
Candida auris in an Australian health care facility: importance of screening high risk patientsLeon J Worth, Simon J Harrison, Michael Dickinson, et al.
Advances in Therapy|February 2, 2026
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect ComparisonNieves Lopez-Muñoz, Noffar Bar, Joris Diels, et al.
British Journal of Haematology|October 27, 2024
Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T-cell period: Preservation of vaccine-associated antibodies between 0 and 6 monthsGemma K Reynolds, Emily Klimevski, Natalie R Saunders, et al.
Blood|August 31, 2019
Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndromeCrystal Gao, Christopher McCormack, Carrie van der Weyden, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
Blood|February 5, 2011
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopeniaMark J Bishton, Simon J Harrison, Benjamin P Martin, et al.
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
Leukemia & Lymphoma|July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantSimon J Harrison, Andy K Hsu, Paul Neeson, et al.
Pageof 16